Insights

Innovative Drug Delivery UroGen Pharma's proprietary RTGel reverse-thermal hydrogel technology offers potential for partnerships with companies seeking enhanced localized drug therapies, particularly in oncology and urology, creating opportunities for licensing or co-development deals.

Growing Pipeline With multiple candidates progressing from pre-clinical to Phase 3 trials, the company provides a robust pipeline that could attract collaboration or investment from pharmaceutical firms aiming to expand their portfolios in urology and oncology sectors.

Market Expansion Recent product launches and continuous participation in prominent biotech conferences suggest UroGen's active push into new markets and partnerships, making it a strategic point of engagement for organizations interested in innovative medical solutions.

Financial Growth Potential Although UroGen reports revenue between 50 to 100 million dollars, the planned $250 million financing indicates significant growth ambitions and investment opportunities for stakeholders interested in biotech financing and expansion.

Securities and Risk Awareness Recent legal and securities fraud issues related to clinical study disclosures highlight an area for cautious engagement but may also signal upcoming restructuring opportunities or readiness for strategic partnership once regulatory concerns are addressed.

UroGen Pharma Tech Stack

UroGen Pharma uses 8 technology products and services including Power BI, CCPA, Microsoft Word, and more. Explore UroGen Pharma's tech stack below.

  • Power BI
    Business Intelligence
  • CCPA
    Certificates
  • Microsoft Word
    Office Suites
  • Microsoft Azure
    Platform As A Service
  • Python
    Programming Languages
  • Google Tag Manager
    Tag Management
  • Google Analytics
    Web Analytics
  • Twitter
    Widgets

Media & News

UroGen Pharma's Email Address Formats

UroGen Pharma uses at least 1 format(s):
UroGen Pharma Email FormatsExamplePercentage
First.Last@urogen.comJohn.Doe@urogen.com
91%
FirstL@urogen.comJohnD@urogen.com
8%
First.Middle@urogen.comJohn.Michael@urogen.com
1%

Frequently Asked Questions

Where is UroGen Pharma's headquarters located?

Minus sign iconPlus sign icon
UroGen Pharma's main headquarters is located at 400 Alexander Park Drive 4th Floor Princeton, New Jersey United States. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is UroGen Pharma's official website and social media links?

Minus sign iconPlus sign icon
UroGen Pharma's official website is urogen.com and has social profiles on LinkedInCrunchbase.

What is UroGen Pharma's SIC code NAICS code?

Minus sign iconPlus sign icon
UroGen Pharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does UroGen Pharma have currently?

Minus sign iconPlus sign icon
As of March 2026, UroGen Pharma has approximately 317 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Ceo: L. B.Chief Commercial Officer: D. L.Chief Financial Officer: C. D.. Explore UroGen Pharma's employee directory with LeadIQ.

What industry does UroGen Pharma belong to?

Minus sign iconPlus sign icon
UroGen Pharma operates in the Biotechnology Research industry.

What technology does UroGen Pharma use?

Minus sign iconPlus sign icon
UroGen Pharma's tech stack includes Power BICCPAMicrosoft WordMicrosoft AzurePythonGoogle Tag ManagerGoogle AnalyticsTwitter.

What is UroGen Pharma's email format?

Minus sign iconPlus sign icon
UroGen Pharma's email format typically follows the pattern of First.Last@urogen.com. Find more UroGen Pharma email formats with LeadIQ.

When was UroGen Pharma founded?

Minus sign iconPlus sign icon
UroGen Pharma was founded in 2004.

UroGen Pharma

Biotechnology ResearchNew Jersey, United States201-500 Employees

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. 

Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment.

Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology.

Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

Section iconCompany Overview

Headquarters
400 Alexander Park Drive 4th Floor Princeton, New Jersey United States
Website
urogen.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
201-500

Section iconFunding & Financials

  • $50M$100M

    UroGen Pharma's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    UroGen Pharma's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.